NervGen Pharma Corp.: NervGen Pharma Reports First Quarter 2021 Results
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its financial results for the first quarter ended March 31, 2021. We achieved several key milestones in the first quarter of 2021 including receiving clearance from the FDA to proceed with our Phase 1 clinical trial for our lead compound, NVG-291, which has now commenced in Australia, stated Paul Brennan, NervGen s President & CEO. In addition, we established an Alzheimer s Disease Scientific Advisory Board comprised of world-class scientists and clinical researchers in Alzheimer s disease and have decided to initiate a multi-dose Alzheimer s disease patient cohort as a Phase 1b addition to our clinical program. We also received Orphan Designation for NVG-291 from the European Medicines Agenc
Vancouver, British Columbia (Newsfile Corp. - April 22, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions